Aktie CONTEXT THERAPEUTICS INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Context Therapeutics Inc.

Aktien

US21077P1084

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Context Therapeutics Announces FDA Clearance of IND Application for A Phase 1 Clinical Trial of CTIM-76
Context Therapeutics Inc. announced that it expects to receive $99.992767 million in funding
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Context Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Context Therapeutics Inc. Amends its Collaboration and Licensing Agreement with Integral Molecular, Inc
Context Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update
Context Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Context Therapeutics to Participate in Two August 2023 Investor Conferences
Context Therapeutics shares #ASCO23 data on CLDN-6 targeted treatments and CTIM-76 update
Traders Insights: These Biotech Stocks On Radar: VSTM, SNTX, CGEN, SONN
CONTEXT THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
Testicular Cancer Pipeline Assessment, FDA Approvals, Clinical Trials, Emerging Drugs, and Therapeutics Assessment 2023 | Major Companies - Sanofi, Seagen Inc., BioNTech, Seagen, and Others
Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Context Therapeutics CTIM-76 bispecific antibody preclinical data presented at AACR Annual Meeting
CONTEXT THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
CONTEXT THERAPEUTICS INC. : Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities (form 8-K)
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
Context Therapeutics announces positive responses in Phase 2 OATH clinical trial
CONTEXT THERAPEUTICS INC. : Regulation FD Disclosure (form 8-K)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. Aktie
  4. Nachrichten Context Therapeutics Inc.
  5. Andere Sprachen